{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:44:12Z","timestamp":1792518252174,"version":"4.5.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:00:00Z","timestamp":1709856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Vericiguat, the newest soluble guanylate cyclase (sGC) drug, is potentially beneficial in treating heart failure (HF). However, most studies have only confirmed the significant impact of sGC in patients with reduced left ventricular ejection fraction (LVEF). Therefore, the main objective of this meta-analysis was to comparatively analyze the effects of Vericiguat in the entire LVEF range based on previous studies. According to PubMed, Web of Science, Cochrane, and Embase databases, randomized controlled studies in the full LVEF stage range were screened, and two extensive clinical studies on Vericiguat, namely VICTORIA (LVEF&amp;lt;45%) and VITALITY-HFpEF (LVEF\u226545%) were identified for analysis and systematic evaluation. We separately assessed the rates of primary outcomes, cardiovascular death, and serious adverse events in both studies. The results of our research confirmed that although the criteria for the primary outcome were not the same in the two extensive studies, it was evident that there was no difference in the primary outcome between the experimental Vericiguat group and the placebo group in the VITALITY-HFpEF (LVEF\u226545%) (P=0.45), whereas the primary outcome of VICTORIA (LVEF&amp;lt;45%) was significantly improved with the administration of Vericiguat showing a significant improvement (RR 0.93; 95% CI 0.87 to 1.00), but the effect of Vericiguat on cardiovascular mortality was not significant across the full range of LVEF (RR 0.97; 95% CI 0.86 to 1.09), and the incidence of total serious adverse events did not differ significantly between the two studies (RR 0.96; 95% CI 0.89 to 1.03). Surprisingly, partial subgroups analysis of serious adverse events found that vericiguat treatment reduced the incidence of all-cause death, Cardiac disorders, Hypotension, and Hypertension in patients with LVEF&amp;lt;45%, with a particular effect on the incidence of Cardiac disorders. Taken together, Vericiguat had a significant benefit in HF patients with LVEF&amp;lt;45%, especially in patients with LVEF&amp;lt;24%; it had a less pronounced effect in HF patients with LVEF \u226545%, but no adverse effects were observed.<\/jats:p>","DOI":"10.3389\/fendo.2024.1335531","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T04:43:52Z","timestamp":1709873032000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Vericiguat in patients with heart failure across the spectrum of left ventricular ejection fraction: a patient-level, pooled meta-analysis of VITALITY-HFpEF and VICTORIA"],"prefix":"10.3389","volume":"15","author":[{"given":"Chao","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changzhao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","article-title":"Heart disease and stroke statistics-2023 update: A report from the American heart association","volume":"147","author":"Tsao","year":"2023","journal-title":"Circulation"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000950","article-title":"Heart disease and stroke statistics-2021 update: A report from the American heart association","volume":"143","author":"Virani","year":"2021","journal-title":"Circulation"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2023.3900","article-title":"Realigning priorities in the evaluation and management of patients with heart failure","volume":"8","author":"Udelson","year":"2023","journal-title":"JAMA Cardiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.7326\/M23-2328","article-title":"Development and validation of a protein risk score for mortality in heart failure: A community cohort study","volume":"177","author":"Kuku","year":"2024","journal-title":"Ann Internal Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2024.01.014","article-title":"Heart failure with improved ejection fraction: Beyond diagnosis to trajectory analysis","author":"Pensa","year":"2024","journal-title":"Prog Cardiovasc Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.15922","article-title":"Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial","volume":"324","author":"Armstrong","year":"2020","journal-title":"Jama"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2022.12.014","article-title":"Ejection fraction, biomarkers, and outcomes and impact of vericiguat on outcomes across EF in VICTORIA","volume":"11","author":"Butler","year":"2023","journal-title":"JACC. Heart Failure"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.813","article-title":"Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry","volume":"19","author":"Chioncel","year":"2017","journal-title":"Eur J Heart Failure"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-021-00487-5","article-title":"The sGC-cGMP signaling pathway as a potential therapeutic target in doxorubicin-induced heart failure: A narrative review","volume":"22","author":"Cho","year":"2022","journal-title":"Am J Cardiovasc drugs: drugs devices other Interventions"},{"key":"B11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ahj.2021.07.003","article-title":"Impact of oral soluble guanylate cyclase stimulators in heart failure: A systematic review and Meta-analysis of randomized controlled trials","volume":"241","author":"Moghaddam","year":"2021","journal-title":"Am Heart J"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/cells12141903","article-title":"Targeting soluble guanylyl cyclase during ischemia and reperfusion","volume":"12","author":"Mace","year":"2023","journal-title":"Cells"},{"key":"B13","doi-asserted-by":"publisher","first-page":"12866","DOI":"10.3390\/ijms241612866","article-title":"New therapeutics for heart failure: focusing on cGMP signaling","volume":"24","author":"Mangmool","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"11826","DOI":"10.3390\/ijms241411826","article-title":"Grimm D. A systematic review of the effect of vericiguat on patients with heart failure","volume":"24","author":"Sahana","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B15","doi-asserted-by":"publisher","first-page":"112894","DOI":"10.1016\/j.biopha.2022.112894","article-title":"Development of vericiguat: The first soluble guanylate cyclase (sGC) stimulator launched for heart failure with reduced ejection fraction (HFrEF)","volume":"149","author":"Xia","year":"2022","journal-title":"Biomedicine pharmacotherapy = Biomedecine Pharmacotherapie"},{"key":"B16","doi-asserted-by":"publisher","first-page":"122184","DOI":"10.1016\/j.lfs.2023.122184","article-title":"Vericiguat alleviates ventricular remodeling and arrhythmias in mouse models of myocardial infarction via CaMKII signaling","volume":"334","author":"Chen","year":"2023","journal-title":"Life Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2720","article-title":"Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum","volume":"24","author":"Butler","year":"2022","journal-title":"Eur J Heart Failure"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2511","article-title":"Is targeting cyclic guanosine monophosphate by vericiguat effective to treat ischaemic heart failure with reduced ejection fraction? Yes, it is","volume":"24","author":"Emdin","year":"2022","journal-title":"Eur J Heart Failure"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1664","article-title":"Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial","volume":"21","author":"Pieske","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"B20","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jchf.2022.11.015","article-title":"Patient-reported frailty and functional status in heart failure with preserved ejection fraction: insights from VITALITY-HFpEF","volume":"11","author":"Kaul","year":"2023","journal-title":"JACC. Heart Failure"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12933-023-02042-9","article-title":"Effects of SGLT2 inhibitors on cardiac function and health status in chronic heart failure: a systematic review and meta-analysis","volume":"23","author":"Chen","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2023.06.020","article-title":"Age, sex, and outcomes in heart failure with reduced EF: insights from the VICTORIA trial","volume":"11","author":"Lam","year":"2023","journal-title":"JACC. Heart Failure"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.6455","article-title":"Clinical outcomes and response to vericiguat according to index heart failure event: insights from the VICTORIA trial","volume":"6","author":"Lam","year":"2021","journal-title":"JAMA Cardiol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2468","article-title":"Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction","volume":"24","author":"Saldarriaga","year":"2022","journal-title":"Eur J Heart Failure"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3044","article-title":"Calcium channel blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction","volume":"25","author":"Matsumoto","year":"2023","journal-title":"Eur J Heart Failure"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2023.10.008","article-title":"The current best drug treatment for hypertensive heart failure with preserved ejection fraction","volume":"120","author":"Rist","year":"2023","journal-title":"Eur J Internal Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14654","article-title":"An altered plasma lipidome-phenome network characterizes heart failure with preserved ejection fraction","author":"Jovanovic","year":"2024","journal-title":"ESC Heart Failure"},{"key":"B28","doi-asserted-by":"publisher","first-page":"101382","DOI":"10.1016\/j.xcrm.2023.101382","article-title":"Sex-stratified genome-wide association and transcriptome-wide Mendelian randomization studies reveal drug targets of heart failure","volume":"11","author":"Yang","year":"2024","journal-title":"Cell Rep Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"68","DOI":"10.18087\/cardio.2023.5.n2422","article-title":"[Soluble guanylate cyclase: restoration of the NO-sGC-cGMP signaling pathway activity. A new opportunity in the treatment of heart failure]","volume":"63","author":"Belenkov","year":"2023","journal-title":"Kardiologiia"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.00345","article-title":"Enhanced cardiomyocyte function in hypertensive rats with diastolic dysfunction and human heart failure patients after acute treatment with soluble guanylyl cyclase (sGC) activator","volume":"11","author":"Kolijn","year":"2020","journal-title":"Front Physiol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/cvr\/cvaa123","article-title":"Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase G\u03b1 oxidation","volume":"117","author":"Kolijn","year":"2021","journal-title":"Cardiovasc Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1007\/s10741-022-10239-5","article-title":"Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure","volume":"27","author":"Triposkiadis","year":"2022","journal-title":"Heart Failure Rev"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2009.01342.x","article-title":"Nitroglycerin headache and nitroglycerin-induced primary headaches from 1846 and onwards: a historical overview and an update","volume":"49","author":"Tfelt-Hansen","year":"2009","journal-title":"Headache"},{"key":"B34","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.yjmcc.2021.09.005","article-title":"Smooth muscle cell CYB5R3 preserves cardiac and vascular function under chronic hypoxic stress","volume":"162","author":"Durgin","year":"2022","journal-title":"J Mol Cell Cardiol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.925457","article-title":"Mapping of the sGC stimulator BAY 41-2272 binding site on H-NOX domain and its regulation by the redox state of the heme","volume":"10","author":"Makrynitsa","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2018.08.009","article-title":"Modulation of nitric oxide-stimulated soluble guanylyl cyclase activity by cytoskeleton-associated proteins in vascular smooth muscle","volume":"156","author":"Kollau","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2023.02.017","article-title":"Stimulation of erythrocyte soluble guanylyl cyclase induces cGMP export and cardioprotection in type 2 diabetes","volume":"8","author":"Jiao","year":"2023","journal-title":"JACC. Basic to Trans Sci"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvaa247","article-title":"Vericiguat in worsening heart failure: agonising over, or celebrating, agonism in the VICTORIA trial","volume":"116","author":"Lang","year":"2020","journal-title":"Cardiovasc Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01586-y","article-title":"Drug treatment of heart failure with reduced ejection fraction: defining the role of vericiguat","volume":"81","author":"Coats","year":"2021","journal-title":"Drugs"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.2174\/1389557519666190730110600","article-title":"Soluble guanylate cyclase stimulators and activators: where are we and where to go","volume":"19","author":"Xiao","year":"2019","journal-title":"Mini Rev Medicinal Chem"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14549","article-title":"Vericiguat: a fifth cornerstone in the treatment of heart failure with reduced ejection fraction","volume":"10","author":"Hammer","year":"2023","journal-title":"ESC Heart Failure"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14647","article-title":"Role of vericiguat in management of patients with heart failure with reduced ejection fraction after worsening episode","author":"Olivella","year":"2023","journal-title":"ESC Heart Failure"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2022.11.007","article-title":"Applicability of vericiguat to patients hospitalized for heart failure in the United States","volume":"11","author":"Khan","year":"2023","journal-title":"JACC. Heart Failure"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.niox.2024.01.007","article-title":"In vivo testing of novel nitric oxide-releasing nanoparticles for alleviating heart failure using the zebrafish embryo model","volume":"144","author":"Hasan","year":"2024","journal-title":"Nitric oxide: Biol Chem"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/164_2016_100","article-title":"Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure","volume":"243","author":"Breitenstein","year":"2017","journal-title":"Handb Exp Pharmacol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.04.057","article-title":"Management of worsening heart failure with reduced ejection fraction: JACC focus seminar 3\/3","volume":"82","author":"Greene","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.981738","article-title":"Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease","volume":"123","author":"Stasch","year":"2011","journal-title":"Circulation"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1335531\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T04:43:54Z","timestamp":1709873034000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1335531\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,8]]},"references-count":48,"alternative-id":["10.3389\/fendo.2024.1335531"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2024.1335531","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,8]]},"article-number":"1335531"}}